Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

DEFERIPRONE vs DELANDISTROGENE MOXEPARVOVEC-ROKL: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

DEFERIPRONE vs DELANDISTROGENE MOXEPARVOVEC-ROKL: Safety Overview

Metric DEFERIPRONE DELANDISTROGENE MOXEPARVOVEC-ROKL
Total FAERS Reports 2,487 196
Deaths Reported 287 6
Death Rate 11.5% 3.1%
Hospitalizations 923 102
Average Patient Age 41.7 yrs 8.7 yrs
% Female Patients 57.4% 2.4%
FDA Approval Date Apr 20, 2018 N/A
Manufacturer Chiesi USA, Inc. Sarepta Therapeutics, Inc.
Route ORAL INTRAVENOUS
Marketing Status Prescription N/A